BFRI insider transaction filings
Biofrontera Inc. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen BFRI transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Leffler Eugene Frederick — Chief Financial Officer | 1 | — | — | 2 |
| Luebbert Hermann — CEO & Chairman, Director | 1 | — | — | 2 |
Recent Form 4 filings — Biofrontera Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | Luebbert Hermann — CEO & Chairman, Director | Option exercise (M): 62,500 · Option exercise (M): 62,500 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Leffler Eugene Frederick — Chief Financial Officer | Option exercise (M): 31,250 · Option exercise (M): 31,250 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Weber Kevin Daniel — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Luebbert Hermann — CEO & Chairman, Director | Option exercise (M): 137,500 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0 · Option exercise (M): 137,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Leffler Eugene Frederick — Chief Financial Officer | Option exercise (M): 87,500 · Grant/award (A): 62,500 (derivative) @ $0 · Grant/award (A): 62,500 (derivative) @ $0 · Option exercise (M): 87,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Lanckriet Heikki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Hoffman Beth J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Jones George Patrick — Chief Commercial Officer | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | BORER JOHN J III — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4 | Biofrontera AG — Director, 10% owner | Purchase (P): 3,019 (derivative) | EDGAR |
| 2025-09-16 | 4 | Jones George Patrick — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Weber Kevin Daniel — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Luebbert Hermann — CEO & Chairman, Director | Option exercise (M): 137,500 · Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 125,000 (derivative) @ $0 · Option exercise (M): 137,500 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Leffler Eugene Frederick — Chief Financial Officer | Option exercise (M): 87,500 · Grant/award (A): 62,500 (derivative) @ $0 · Grant/award (A): 62,500 (derivative) @ $0 · Option exercise (M): 87,500 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Lanckriet Heikki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | Hoffman Beth J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | BORER JOHN J III — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Weber Kevin Daniel — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Luebbert Hermann — CEO & Chairman, Director | Grant/award (A): 275,000 (derivative) @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Leffler Eugene Frederick — Chief Financial Officer | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Lanckriet Heikki — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | Hoffman Beth J. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-07-16 | 4 | BORER JOHN J III — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Luebbert Hermann — CEO & Exec. Chairman, Director | Option exercise (M): 4,771 · Option exercise (M): 4,771 (derivative) @ $0 | EDGAR |
Recent 8-K events — Biofrontera Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BFRI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →